Protagonist Therapeutics (PTGX) Accumulated Expenses (2015 - 2026)

Protagonist Therapeutics (PTGX) has 12 years of Accumulated Expenses data on file, last reported at $17.5 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 47.69% year-over-year to $17.5 million; the trailing twelve-month figure through Mar 2026 stood at $17.5 million (up 47.69% YoY), and the FY2025 full-year result was $28.3 million, up 19.31% from the prior year.
• Accumulated Expenses fell to $17.5 million in Q1 2026, from $28.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $36.2 million in Q2 2022 to a low of $11.8 million in Q1 2025.
• A 5-year average of $22.1 million and a median of $20.7 million in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses jumped 85.94% in 2022 and slumped 49.54% in 2023, its largest moves.
• Tracing PTGX's Accumulated Expenses over 5 years: stood at $25.0 million in 2022, then declined by 22.43% to $19.4 million in 2023, then increased by 22.39% to $23.7 million in 2024, then rose by 19.31% to $28.3 million in 2025, then tumbled by 38.13% to $17.5 million in 2026.
• Business Quant data shows PTGX's Accumulated Expenses at $17.5 million in Q1 2026, $28.3 million in Q4 2025, and $22.9 million in Q3 2025.